AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02639364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nellcor Puritan Bennett 840 ventilator system
Description: Puritan Bennett 840 ventilator can provide the VCV,PCV,Bi-level Airway Pressure Ventilation-airway Pressure Release Ventilation(BILEVER-APRV) mode.
Study NCT02639364 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nellcor Puritan Bennett 840 ventilator system
Description: Puritan Bennett 840 ventilator can provide the VCV,PCV,Bi-level Airway Pressure Ventilation-airway Pressure Release Ventilation(BILEVER-APRV) mode.
Study NCT03302702 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise program
Description: Exercise program including breathing control, pursed-lip breathing, diaphragmatic and thoracic breathing, aerobic and strengthening training
Study NCT00143611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resatorvid
Description: Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.05 mg/kg/h (1.2 mg/kg/day), injection, subcutaneously over 96 hours.
Study NCT00143611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resatorvid
Description: Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.1 mg/kg/h (2.4 mg/kg/day), injection, subcutaneously over 96 hours.
Study NCT00143611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Resatorvid placebo-matching injection, subcutaneously for thirty minutes; then resatorvid placebo-matching injection, subcutaneously over 96 hours.
Study NCT04358497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic® Concerto® detachable coil system
Description: coil embolization of the reflux pathways
Study NCT04358497 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sclerosis
Description: Pelvic varices sclerosis with polidocanol foam
Study NCT04358497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diosmin / Hesperidin
Description: Best chronic medial treatment
Study NCT04358497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diosmin / Hesperidin
Description: Best chronic medial treatment
Study NCT01005186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating habits, diet and exercise
Description: Programme of change to eating habits, diet and exercise
Study NCT03682211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate
Description: 50 μg/ml fentanyl citrate (Sublimaze, Janssen Cilag, Ltd, Marketing Authorisation No. PA 0748/044/001) administered intranasally using the MAD Nasal Intranasal Mucosal Atomiser Device
Study NCT03682211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine sulphate
Description: 10 mg/ml Morphine sulphate BP (Antigen Pharmaceuticals, Marketing Authorisation No.PA 73/20/1) administered intravenously.
Study NCT04358497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 400 mg
Description: NSAID treatment
Study NCT04358497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: NSAID treatment
Study NCT04237961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Botox and brow lift
Description: Botox injection
Study NCT04237961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection
Description: Fat injection and botox
Study NCT04237961 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture
Description: Suspension suture
Study NCT01521026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: 12-week compensatory cognitive training in group format
Study NCT02348125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitochondrial Cocktail
Study NCT04236388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ketone drink
Description: Pre- and post-testing will be completed before and after participants receive 42 doses of ketone supplement drink over a 2-week period (3x/day for 14 days).
Study NCT04236388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Pre- and post-testing will be completed before and after participants receive 42 doses of placebo supplement drink over a 2-week period (3x/day for 14 days).
Study NCT01402817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutent®/Sunitinib
Description: Upon enrollment, subjects will receive Sutent® orally. Adults (Age >18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg. The maximum dose for children is 15mg/m2/day.
Study NCT00502671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1250mg/m2 po bid on days 1-14 of each 3 week cycle
Study NCT01179581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: single ascending doses, oral solution (1 to 10 mg/dose) and capsules (10 to 200 mg/dose)
Study NCT01179581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose, oral solution or capsule (matching corresponding study medication)
Study NCT01179581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: multiple dose, capsule, 10 days
Study NCT01179581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: multiple dose, capsule, 10 days
Study NCT03627156 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: guided counseling
Description: Community-based guided counseling using Health Belief Model and Theory of Planned Behavior is the intervention package for this study.
Study NCT04065685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: serious game named Go Wish
Description: The nurse led intervention Go Wish is composed of 36 cards presenting statements of personal needs, values, and beliefs about end-of-life care. The aim is to decide about what to put into the patient's file as care options and the subsequent appointments to name a potential surrogate or to elaborate ADs.~Patient and relative (if participating) will meet their nurse twice:~Session 1: patient the cards in three piles and to rank the ten most important. Session 2 without relative: the nurse reiterates the wishes of care and treatments previously expressed and links them to the state of health and symptoms of the patient and the current treatments and their possible evolution.~Session 2 with a relative: the relative sort the cards based on his/her beliefs about the patient's expectation.~Session 3 with a relative: the nurse bring together the patient and his/her relative to discuss the priorities selected independently, identify, and explore the similarities and differences.
Study NCT04065685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Standardized information on anticipated directives (ADs): the imad nurse are trained to promote AD to clients to help nurses to describe and explain ADs, to identify and to mobilize the required interview condition to promote ADs to clients to facilitate and initiate discussion on ADs
Study NCT03119051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online cognitive training
Description: A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%.
Study NCT03932942 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: QIAstat at pediatric emergency room
Description: Pediatric acute care nurses will obtain respiratory samples for testing from all patients with fever or any respiratory symptom.
Study NCT03119051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training plus physical exercise
Description: Online cognitive training A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%.~Physical Exercise Tai Chi Training：a teacher will give two 60-min lessons per week. Participants will play Tai Chi in the lessons, following teacher's instruction.
Study NCT02163499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate
Description: Acute Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) for 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) based on i-STAT potassium measurements up to 12 months.
Study NCT00591448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Description: See above
Study NCT01186185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: Fludrocortisone 0.2 mg by mouth daily for 30 days
Study NCT05191693 — intervention group
Intervention type: PROCEDURE
Intervention: ERCP
Description: endoscopic papillary balloon dilation (EPBD) with endoscopic sphincterotomy (EST
Study NCT04332107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Participants will be shipped a single 1.2 g dose of oral azithromycin
Study NCT04332107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Participants will be shipped a dose of matching placebo
Study NCT00411671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg By Mouth Twice Daily for 28 Days.
Study NCT00883961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Description: The patients will carry out a daily endurance exercise program consisting of walking on a treadmill for 30 minutes at an intensity of about 80% of the maximum heart rate under supervision from study personnel.
Study NCT02944214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body
Study NCT02944214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzbromarone
Description: It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase
Study NCT03951272 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lyoplant® Onlay/DURAFORM™ Dural Graft Implant
Description: Lyoplant® Onlay will be used as a dura substitute for the repair of the duramater.The DURAFORM™ Dural Graft Implant will be used in the procedures where the repair or substitution of the patient's dura mater is needed.
Study NCT03951272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lyoplant® Onlay/DURAFORM™ Dural Graft Implant
Description: Lyoplant® Onlay will be used as a dura substitute for the repair of the duramater.The DURAFORM™ Dural Graft Implant will be used in the procedures where the repair or substitution of the patient's dura mater is needed.
Study NCT02042521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dietary Supplement
Description: The active evening dietary supplement is taken at 22:00. The active morning dietary supplement is taken at 8:00-8:15. The active evening dietary supplement is taken first. The active morning and evening dietary supplements are taken within 12 hours in time points as specified above.
Study NCT02042521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactose Placebo
Description: This research study involves a placebo dietary supplement that does not have any of or only partial of the active ingredients in the active dietary supplement. The placebo dietary supplement will be given in identical time points to match that of the active dietary supplements.
Study NCT03362294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA Depot 40mg once monthly
Description: Once-a-month long-acting intramuscular injection of 40mg Glatiramer Acetate (GA Depot)
Study NCT03362294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GA Depot 25mg once monthly
Description: Once-a-month long-acting intramuscular injection of 25mg Glatiramer Acetate (GA Depot)
Study NCT03176628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Basis
Description: NR is a form of vitamin B3; Pterostilbene is a natural dietary compound and the primary antioxidant component of blueberries
Study NCT03176628 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule(s)
Study NCT03681925 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nutrition Literacy Assessment Instrument (NLit)
Description: The NLit is a 64-question survey broken into 6 subscales. each subscale examines a different aspect of nutrition literacy (Nutrition and Health, Energy Sources in Food, Household Food Measurement, Food Label and Numeracy, Food Groups, and Consumer Skills). Global and subscale NLit scores will be generated for each participating patient.
Study NCT02157181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2CdA +/- Rituximab
Description: Cladribine 0.14 mg/kg daily subcutaneous bolus injection Rituximab 375 mg/m² infusion
Study NCT00669214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efalizumab
Description: All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
Study NCT00669214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: All patients received a conditioning dose of placebo equivalent SC on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).
Study NCT00754377 — intervention group
Intervention type: OTHER
Intervention: PBLI Curriculum
Description: PBLI curriculum was offered on alternate rotations
Study NCT04194268 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon Ion
Description: 12 x 4 Gy (RBE)
Study NCT00726414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine Sulfate 2 x 324 mg Capsules
Description: Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.
Study NCT00726414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine Sulfate 2 x 324 mg Capsules
Description: Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.
Study NCT01635231 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypertonic saline
Description: hypertonic saline 3.0% 7 ml/kg
Study NCT01635231 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: hypertonic saline
Description: hypertonic saline 3.0% 7 ml/kg
Study NCT01165983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0mg tablet, taken orally for 12 weeks daily
Study NCT01165983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: 150mg tablet, taken orally for 12 weeks daily
Study NCT00086047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Skills Training
Description: 8 weekly sessions of behavioral treatment
Study NCT00086047 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: 8 weekly sessions of fibromyalgia education
Study NCT04039958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soviredia
Description: Test drug (Soviredia)1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
Study NCT04039958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Harvoni (first dose)
Description: Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
Study NCT04039958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Harvoni (Second dose)
Description: Reference drug (Harvoni) 1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
Study NCT03202407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium acetate and sevelamer hydrochloride
Description: receive the conventional renal replacement therapy including calcium-based phosphate (calcium acetate) and active form of vitamin D for 3 months with regular follow up of serum phosphate ,calcium, parathyroid hormone and alkaline phosphate every month
Study NCT03202407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium acetate and sevelamer hydrochloride
Description: receive the conventional renal replacement therapy including calcium-based phosphate (calcium acetate) and active form of vitamin D for 3 months with regular follow up of serum phosphate ,calcium, parathyroid hormone and alkaline phosphate every month
Study NCT04494906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive stepping exercise
Description: An exercise intervention based on the principle of square stepping exercise
Study NCT04494906 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Square stepping exercise
Description: Square stepping exercise
Study NCT02818972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RelayPro
Description: Endovascular treatment with investigational device.
Study NCT03571555 — intervention group
Intervention type: BEHAVIORAL
Intervention: Sentebale Psychosocial Programme
Description: Residential interventions (camps) for the young people, and community based support (clubs) for the young people and the caregivers.
Study NCT02137824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sinus floor elevation
Study NCT04627155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03003
Description: Rotigotine,extended-release microspheres
Study NCT01615016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minimally invasive endotracheal surfactant application
Description: What are the planned trial interventions?~1. MISurf: Minimally invasive intratracheal surfactant application without mechanical ventilation by feeding tube device~2. InSurE: Surfactant application by InSurE strategy (Intubation - surfactant - extubation sequence).~Both interventions will be performed by intervention teams. For the MISurf intervention, it was decided to use the minimally invasive method via feeding tube exclusively due to concerns about possibility of airway injury with the iv cannula device.~Surfactant Two porcine derived surfactant products have been used in the published trials for minimal invasive surfactant application, Curosurf© and Survanta©. Due to safety reasons we will use these products also in our pilot study however, only the latter is currently available in Canada. Hence we will use Survanta© 100 mg/kgBW, equivalent to 4 ml/kgBW per dose.19,20,26
Study NCT01615016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimally invasive endotracheal surfactant application
Description: What are the planned trial interventions?~1. MISurf: Minimally invasive intratracheal surfactant application without mechanical ventilation by feeding tube device~2. InSurE: Surfactant application by InSurE strategy (Intubation - surfactant - extubation sequence).~Both interventions will be performed by intervention teams. For the MISurf intervention, it was decided to use the minimally invasive method via feeding tube exclusively due to concerns about possibility of airway injury with the iv cannula device.~Surfactant Two porcine derived surfactant products have been used in the published trials for minimal invasive surfactant application, Curosurf© and Survanta©. Due to safety reasons we will use these products also in our pilot study however, only the latter is currently available in Canada. Hence we will use Survanta© 100 mg/kgBW, equivalent to 4 ml/kgBW per dose.19,20,26
Study NCT02274792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept produced using the serum free process (SFP)2 was supplied in a single-use 1 mL prefilled syringe for subcutaneous injection.
Study NCT04110782 — intervention group
Intervention type: OTHER
Intervention: Radium223
Description: 55 kBq/ Kg
Study NCT04479332 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tracheal intubation and cardiopulmonary resuscitation
Description: Critical patients at the emergency room who require tracheal intubation and/or cardiopulmonary resuscitation will be sequentially allocated to either the resuscitation area or negative pressure isolation room for treatment by the designated medical staff wearing personal protective equipment.
Study NCT02534415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal dressing material
Description: Procedure:Palatal wound area was covered with periodontal dressing material at baseline and 3rd day
Study NCT02534415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2% Hyaluronic acid gel
Description: 0.2% topical hyaluronic-acid gel was applied to palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day